Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (827)	6/6/1999 8:09:00 AM
From: sam_b	Read Replies (1) \| Respond to of 1386

Nerve gas- Special request About a year ago, on June 3rd 1998, Pharmos announced a trial held by the U.S. Army that claimed a 76% success rate in reducing brain damage caused to lab rats exposed to nerve gas by using Dexanabinol. The Israeli press and TV mentioned this announcement. After clarifying this matter with Pharmos I was told that there was no request or comment from any official element in Israel concerning this announcement. In October 1998, after the PII results were published, no application to Pharmos had been received. As an Israeli citizen, I applied by myself to the governmental element qualified to handle these issues, mentioning the potential dangers in our area along with the success of the experiment made in the U.S. I asked to make the same tests in Israel to find if Dexanabinol with Atropine will reduce the damage from nerve gas. Only recently I have received a detailed reply in which I was told that the subject was studied by the relevant elements. I prepared a dossier with articles collected from this board. I wish to send this dossier, with all the relevant articles discussing the issue. I am interested in this point, and ask all readers cooperate by passing over all printed material which may advance this issue. My e-mail address is passim@netvision.net.il. Even though I prefer receiving the information through the YAHOO or S I boards, for two reasons. 1. Preventing duplications and unnecessary media "noise". Articles sent by one sender will not be sent by another. 2. The readers of this board can ,in this way, get update and share information which they maybe not have seen previously (this in itself is a positive goal). Of course, the test protocol and trials made for handling nerve gas is different with regard to aims of testing, times, etc., than the tests to be made by the FDA. On the other hand, it is not necessary to state the degree of importance of these trials succeeding for the success of Pharmos. I call once again , to all readers in this board , able to contribute information to send it to this board including material previously published.( I may have missed something out) I'll send all the relevant articles. with thanks-Sam.